Ivermectin and Mebendazole for Cancer: What Does the Evidence Actually Say?
by
Yoon Hang “John” Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
Yoon Hang Kim MD • directintegrativecare.com
If you’ve spent any time in integrative oncology circles—or even just scrolling health-related social media—you’ve almost certainly encountered claims about ivermectin and mebendazole as cancer treatments. The enthusiasm is understandable. Both are inexpensive, widely available antiparasitic drugs with decades of safety data at standard doses. And the preclinical science is genuinely interesting.
But as a board-certified integrative medicine physician with deep roots in integrative oncology, I want to walk you through what the evidence actually shows—where it’s promising, where it falls short, and what I think patients and clinicians should know before making decisions about these agents.
The Appeal of Drug Repurposing
Before diving into the specifics, it helps to understand why drug repurposing generates so much excitement. Developing a new cancer drug from scratch costs billions and takes over a decade. Repurposing an existing drug—one with established safety profiles, known pharmacokinetics, and existing manufacturing—dramatically shortens that timeline and reduces cost.
Ivermectin and mebendazole are poster children for this concept. They’ve been used safely in hundreds of millions of people worldwide for parasitic infections. The question is whether their anticancer properties, clearly demonstrated in laboratory settings, translate into meaningful clinical benefit in humans.
That translation, as we’ll see, is where caution is warranted.
Ivermectin: The Preclinical Promise
The laboratory data on ivermectin’s anticancer activity is, frankly, impressive in scope 1,2. In vitro and animal studies demonstrate that ivermectin can inhibit cancer cell proliferation, reduce metastatic potential, suppress angiogenesis (the formation of new blood vessels that tumors need to grow), and target cancer stem cells—the subpopulation of cells thought to drive treatment resistance and recurrence 1,2.
The mechanisms are multifaceted. Ivermectin appears to modulate PAK1 kinase and its downstream MEK/ERK signaling cascade 3,4, interfere with WNT/β-catenin and Hedgehog-related pathways (both critical in many cancers) 1,2, and affect the PI3K/AKT pathway 4. It has also been shown to reverse multidrug resistance by modulating EGFR/ERK/Akt/NF-κB signaling and drug-efflux transporters 5. Perhaps most intriguingly, a recent in vitro study reported that ivermectin resensitized endocrine-resistant breast cancer cells (tamoxifen-resistant MCF-7 lines) by suppressing Wnt-mediated epithelial-to-mesenchymal transition 6.
There are also emerging data suggesting immune-modulatory effects, which is particularly relevant in an era where immunotherapy has transformed oncology 7.
Where We Stand Clinically
Here’s where I have to temper the enthusiasm. Despite compelling laboratory work, we do not yet have robust clinical evidence in humans demonstrating that ivermectin reduces cancer growth or improves survival. Major oncology organizations, including Macmillan Cancer Support, have been explicit about this 8.
The most notable active clinical effort is a Phase I/II trial (NCT05318469) at Cedars-Sinai testing ivermectin in combination with balstilimab or pembrolizumab for metastatic triple-negative breast cancer 9. The trial uses an intermittent oral dosing schedule—ivermectin on days 1–3, 8–10, and 15–17 of a 21-day cycle—alongside standard checkpoint-inhibitor dosing 9. Importantly, the primary objectives are dose-finding and safety. This is not a trial designed to prove efficacy; it’s designed to figure out whether the drug can even be dosed safely enough to study further.
Mebendazole: A Stronger Repurposing Case?
Of the two agents, mebendazole arguably has a more developed repurposing literature 10,11. Its mechanism of action as an anti-tubulin agent—inhibiting tubulin polymerization via the colchicine-binding domain—places it in the same mechanistic family as established chemotherapy drugs like vincristine and paclitaxel 10,11. It causes G2/M cell cycle arrest, induces double-strand DNA breaks, and triggers apoptosis across a broad range of cancer cell lines, including lung, breast, ovarian, colon, prostate, and osteosarcoma 10,11.
Beyond direct cytotoxicity, mebendazole shows anti-angiogenic properties through VEGFR2 inhibition, decreased microvessel density, and reduced VEGF and pro-inflammatory cytokine levels 11,12. There’s additional preclinical evidence suggesting it can deplete cancer stem-cell populations and sensitize tumors to both radiation and conventional chemotherapy 11.
The Repurposing Drugs in Oncology (ReDO) project, a collaborative effort specifically evaluating off-patent drugs for anticancer potential, has featured mebendazole prominently 10. The ReDO review and subsequent analyses position it as one of the more promising repurposing candidates 10,11.
The Clinical Gap
Even so, we lack controlled phase III data. Early clinical observations—in glioblastoma, colorectal, and ovarian cancer settings—suggest possible disease stabilization, reduced metastasis, and modest survival benefits in some patients 11. But “suggest” and “some” are doing heavy lifting in that sentence. Case reports and small series, however compelling, cannot substitute for randomized controlled trials.
Phase I work in glioblastoma has explored oral dosing up to approximately 200 mg/kg/day in combination with temozolomide, demonstrating acceptable long-term safety with reversible grade 3 transaminase elevations as the main toxicity at the highest dose 13. A separate Phase I study of mebendazole in recurrent high-grade glioma established fixed-dose regimens (up to 1,600 mg three times daily) in combination with temozolomide or CCNU, with anemia, nausea, and fatigue as the dominant adverse events 14. Preclinical work has identified mebendazole polymorph C as having superior blood–brain barrier penetration (brain-to-plasma ratio ~0.8) compared with polymorph A, informing ongoing efforts to optimize CNS formulations 12,14. These regimens are dramatically higher than standard antiparasitic dosing and introduce a different safety profile entirely.
These are experimental regimens. They are not standardized.
The Combination Question
This is perhaps the most important section of this article, because it addresses what many patients are actually asking about: using ivermectin and mebendazole together as a cancer treatment protocol.
The direct answer is that published human data on a deliberate ivermectin-plus-mebendazole combination regimen for cancer are extremely sparse. Most of the literature addresses each agent separately, or in combination with standard chemotherapy, radiation, or immunotherapy—not with each other 1,10,11.
A practice-oriented literature for compounding pharmacists describes the theoretical oncology use of both drugs, references case reports where these agents appeared as part of multi-drug regimens, and acknowledges that oncology dosing often exceeds antiparasitic doses—while explicitly stating that optimal dosing and protocols remain undefined.
No major guideline-level source, no large clinical trial, and no professional oncology organization currently endorses a specific ivermectin-plus-mebendazole protocol—dose, schedule, or duration—for any cancer type. The regimens described in case reports are heterogeneous and unvalidated.
I know that’s not what many readers want to hear. But intellectual honesty requires saying it clearly.
Safety Considerations
Part of what makes these drugs attractive is their reputation for safety—and at standard antiparasitic doses, that reputation is well-earned. But oncology dosing is a different conversation.
Ivermectin at high or prolonged doses can cause neurotoxicity, including ataxia, confusion, and seizures, and interacts with drugs affecting P-glycoprotein and CYP3A4—relevant because many cancer patients are on multiple medications metabolized through these pathways 2.
Mebendazole at oncology-level doses carries documented risks of hepatotoxicity and bone marrow suppression, including anemia and neutropenia 13,14. It should not be combined with metronidazole due to an increased risk of Stevens–Johnson syndrome/toxic epidermal necrolysis; an outbreak among Filipino laborers in Taiwan established the association, with a nearly tenfold increase in risk among co-exposed individuals 15. Patients using mebendazole at higher doses require monitoring of liver function and complete blood counts.
These aren’t theoretical concerns. They are documented adverse effects at the dose ranges being explored for cancer.
My Clinical Perspective
As someone who has spent over two decades in integrative medicine, including integrative oncology work at academic medical centers, I want to offer a nuanced take that goes beyond “it doesn’t work” or “it’s a miracle cure.”
The preclinical science is legitimate and warrants further investigation. Mebendazole’s anti-tubulin mechanism is pharmacologically sound. Ivermectin’s multi-pathway activity is biologically plausible. Drug repurposing is a rational and important strategy in oncology 16.
But preclinical promise does not equal clinical proof. The history of oncology is littered with agents that showed dramatic activity in cell lines and animal models but failed to benefit patients in controlled trials. The gap between petri dish and patient is wide, and crossing it requires rigorous clinical evaluation.
What concerns me most is when patients use these agents as a substitute for proven therapies. Conventional oncology organizations have warned—and I agree—that using ivermectin or mebendazole as primary cancer treatment instead of evidence-based therapies is associated with worse outcomes 8.
Where I see potential is in the adjunctive setting—as additions to standard therapy, under careful medical supervision, with appropriate monitoring, ideally within the context of a clinical trial. This is the approach that respects both the patient’s interest in exploring every avenue and the scientific principle of first, do no harm.
What Should You Do With This Information?
If you or a loved one is exploring ivermectin, mebendazole, or both as part of a cancer care strategy, here are five principles worth holding onto:
- Don’t self-medicate. Oncology dosing of these drugs is fundamentally different from antiparasitic use, and the risks scale accordingly. You need medical oversight, baseline labs, and ongoing monitoring.
- Don’t replace proven therapy. If you have a cancer for which effective conventional treatments exist, those should remain the backbone of your treatment plan. Adjunctive exploration is reasonable; substitution is not.
- Seek clinical trial participation if possible. The ivermectin-plus-checkpoint-inhibitor trial in triple-negative breast cancer is one example 9. If you have a cancer type where trials are enrolling, this is the best way to access these agents with the safety infrastructure of a research setting.
- Work with a physician who understands both integrative and conventional oncology. This is not a supplement you pick up at the health food store. It requires clinical judgment about dosing, drug interactions, monitoring parameters, and the broader treatment context.
- Stay evidence-informed, not evidence-limited. There’s a difference between dismissing emerging research out of hand and accepting it uncritically. The goal is honest engagement with the data as it stands today—promising, preliminary, and not yet practice-changing.
The Bottom Line
Ivermectin and mebendazole represent genuinely interesting candidates for drug repurposing in oncology. The preclinical data, particularly for mebendazole, is substantive 10,11. But no validated human protocol exists for either drug—alone or in combination—for any cancer type. The regimens circulating online and in some clinical communities are experimental, heterogeneous, and not backed by the kind of evidence we would need to recommend them as standard care.
Science moves forward. Trials are underway. I am cautiously optimistic that some of these questions will be answered in the coming years. But until they are, the responsible path is careful, supervised, adjunctive exploration—not unsupervised self-treatment, and not abandonment of proven therapies.
References
1. Tang M, Hu X, Wang Y, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021;163:105207. doi:10.1016/j.phrs.2020.105207
2. Liu J, Zhang K, Cheng L, Zhu H, Xu T. Progress in understanding the molecular mechanisms underlying the antitumour effects of ivermectin. Drug Des Devel Ther. 2020;14:285–296. doi:10.2147/DDDT.S237393
3. Hashimoto H, Messerli SM, Sudo T, Maruta H. Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther. 2009;3(6):243–246.
4. Dou Q, Chen HN, Wang K, et al. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Res. 2016;76(15):4457–4469. doi:10.1158/0008-5472.CAN-15-2887
5. Jiang L, Wang P, Sun YJ, Wu YJ. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019;38(1):265. doi:10.1186/s13046-019-1251-7
6. Suwannakul N, Chusuwan N, Tomya M, et al. Ivermectin inhibits epithelial-to-mesenchymal transition via Wnt signaling in endocrine-resistant breast cancer cells. PLoS One. 2025;20(6):e0326742. doi:10.1371/journal.pone.0326742
7. Draganov D, Gopalakrishna-Pillai S, Chen YR, et al. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer. 2021;7:22. doi:10.1038/s41523-021-00229-5
8. Simcock R. Cancer and ivermectin: what people with cancer need to know. Macmillan Cancer Support. Available at: https://www.macmillan.org.uk/about-us/latest-news/news-and-stories/cancer-and-ivermectin
9. ClinicalTrials.gov. A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab or Pembrolizumab in Patients with Metastatic Triple Negative Breast Cancer. NCT05318469. Cedars-Sinai Medical Center. Available at: https://clinicaltrials.gov/study/NCT05318469
10. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in oncology (ReDO)—mebendazole as an anti-cancer agent. Ecancermedicalscience. 2014;8:443. doi:10.3332/ecancer.2014.443
11. Guerini AE, Triggiani L, Maddalo M, et al. Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature. Cancers (Basel). 2019;11(9):1284. doi:10.3390/cancers11091284
12. Bai RY, Staedtke V, Rudin CM, Bunz F, Riggins GJ. Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro Oncol. 2015;17(4):545–554. doi:10.1093/neuonc/nou234
13. Gallia GL, Holdhoff M, Brem H, et al. Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. Neurooncol Adv. 2021;3(1):vdaa154. doi:10.1093/noajnl/vdaa154
14. Patil VM, Bhelekar A, Menon N, et al. Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma. Cancer Med. 2020;9(13):4676–4685. doi:10.1002/cam4.3094
15. Chen KT, Twu SJ, Chang HJ, Lin RS. Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. Am J Public Health. 2003;93(3):489–492. doi:10.2105/ajph.93.3.489
16. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience. 2014;8:442. doi:10.3332/ecancer.2014.442
© Yoon Hang Kim MD www.directintegrativecare.com All rights reserved.
